Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Treatment Guidelines and Pharmacotherapy Options

Credits Available
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: April 8, 2022 Expiration: April 7, 2023
Start Activity
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.
Megan Adelman, PharmD, BCPS, BCGP, CDCES
Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize treatment guidelines, lifestyle modifications, and evidence-based pharmacotherapy options for the management of obesity

Information on this Educational Activity

ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Megan Adelman, PharmD, BCPS, BCGP, CDCES

Clinical Pharmacist - Family Medicine
Center for Family Medicine
Cleveland Clinic Akron General
Akron, Ohio

Megan Adelman, PharmD, BCPS, BCGP, CDCES, has no relevant conflicts of interest to report.
Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA

Professor 
Department of Pharmacy Practice
College of Pharmacy-Glendale
Midwestern University
Glendale, Arizona

Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA, has no relevant conflicts of interest to report.

Staff

Robin Black, PharmD, BCACP

Scientific Director

Robin Black, PharmD, BCACP, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran D. Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The target audience for this program is pharmacists, including clinical, community, specialty, and managed care pharmacists who care for patients with obesity, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Goal

The goal of this activity is to improve the knowledge and competence of pharmacists regarding obesity management, with an emphasis on the safe use, dosing, titration, and administration of injectable obesity treatment options.

CE Accreditation

Continuing Pharmacy Education

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-041-H01-P has been assigned to this home study, knowledge-based activity. This activity is approved for 0.5 contact hour (0.05 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Completion of an evaluation and post-test with a score of 100% or higher is required to receive CE credit. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.50 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 08, 2022, through April 07, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Treatment Guidelines and Pharmacotherapy Options

Loading...
In this microlearning module, an expert faculty summarizes obesity guideline recommendations, including lifestyle modifications and pharmacotherapy options.
Megan Adelman, PharmD, BCPS, BCGP, CDCES
Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: April 8, 2022 Expiration: April 7, 2023

Related Content

Expert faculty provide practical strategies for successful implementation of digital techonologies to improve diabetes outcomes from ProCE

Andrew Bzowyckyi, PharmD, BCPS, CDCES Diana Isaacs, PharmD, BCPS, BCACP, CDCES, BC-ADM, FADCES, FCCP Pharmacists: 1.5 contact hours (0.15 CEUs) Released: April 18, 2022 Expired: April 17, 2023

Downloadable slides featuring expert insight on obesity, including guideline recommendations and a review of available pharmacotherapy, from ProCE

Released: April 12, 2022

Downloadable slides featuring expert insight on obesity, including guideline recommendations and a review of available pharmacotherapy, from ProCE

Released: April 12, 2022

A quick reference guide for initiation of GLP-1 RAs for treatment of obesity, from ProCE

Megan Adelman, PharmD, BCPS, BCGP, CDCES Elizabeth Pogge, PharmD, MPH, BCPS-AQ Cardiology, BCGP, FASCP, FAzPA Released: April 11, 2022
Provided by ProCE, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings